Hypertension Trial, Recruiting NCT07688928 Sponsor: Bangladesh Medical University Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT07688928
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have high blood pressure (readings above 140/90 mmHg), whether newly found or already known
  • People who have been diagnosed with a condition called primary aldosteronism (a hormone-related cause of high blood pressure), confirmed through two specific blood tests measuring hormone levels (confirm with trial site for exact test details)
  • People whose blood potassium level is at or above 2.5 mmol/L on a blood test

Who may not be able to join:

  • People whose blood pressure is severely uncontrolled, with readings above 180/120 mmHg
  • People whose primary aldosteronism is caused by a single overactive gland or a tumour on one side, and who are planning to have that gland surgically removed, or who have a cancerous aldosterone-producing tumour
  • People who are already taking a type of medication known as a mineralocorticoid receptor antagonist
  • People taking certain medications — including some steroids, a group of diabetes drugs called SGLT-2 inhibitors, or specific antifungal, antibiotic, or anti-seizure drugs — that cannot be safely stopped at least 14 days before the trial starts and kept stopped for the whole treatment period (confirm with trial site which specific medications apply)
  • People whose kidneys are not working well enough, based on a blood test showing reduced kidney filtering function (eGFR below 60)
  • People whose blood potassium level is above 5 mmol/L on a blood test
  • People who have had a recent serious heart or stroke event — such as a heart attack, a hospitalisation for heart failure, a stroke, or a mini-stroke — within the three months before the screening visit
  • People with poorly controlled diabetes, based on a blood sugar measure (HbA1c) above 12%
  • People with severe liver disease (classified as Child-Pugh C) (confirm with trial site)
  • People with a condition called Addison's disease (a disorder where the adrenal glands do not produce enough hormones)
  • Women who are pregnant or breastfeeding; women who could become pregnant would need to agree to use reliable contraception throughout the trial and for two months after it ends
  • People whose high blood pressure is caused by another identified medical condition other than primary aldosteronism, such as a narrowed kidney artery, Cushing's syndrome, a tumour called a phaeochromocytoma, or a narrowing of the main heart artery
  • People who have had an allergic reaction to the medications being studied in this trial
  • People who are not willing to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sharmin Jahan, PhD, Professor

Phone: +8801731061056

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bangladesh Medical University
Registry
ClinicalTrials.gov
Start date
15 April 2026
Est. completion
1 March 2027

Where this trial is recruiting

Bangladesh

Primary endpoints

Dose of Finerenone; Time required

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov